{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:17:48Z","timestamp":1770967068524,"version":"3.50.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:p>Autologous stem cell transplant (ASCT) has been an important component of therapy for myeloma patients eligible for high-dose chemotherapy. Recent studies comparing early transplant to low-dose chemotherapy support the continued use of ASCT as consolidation following induction therapy, even in the era of immunomodulatory drugs, proteasome inhibitors, and other novel agents. Despite the marked improvements in outcomes with this approach, most patients will eventually experience disease progression. Thus, inclusion of post-ASCT consolidation\/maintenance strategies is used to improve long-term disease control. Multiple randomized studies support the use of lenalidomide maintenance therapy following ASCT. The next generation of clinical trials will incorporate novel agents such as monoclonal antibodies, proteasome inhibitors, and other novel pathway modulatory agents into post-ASCT treatment strategies with the goal of achieving even deeper responses and longer durations of disease control.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.504","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"504-511","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Role of stem cell transplant and maintenance therapy in plasma cell disorders"],"prefix":"10.1182","volume":"2016","author":[{"given":"Philip L.","family":"McCarthy","sequence":"first","affiliation":[{"name":"Department of Medicine, Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Holstein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"12","key":"2019111706011775600_B1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"2019111706011775600_B2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/bmt.2015.106","article-title":"High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma","volume":"50","author":"Wildes","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111706011775600_B3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111706011775600_B4","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111706011775600_B5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2019111706011775600_B6","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111706011775600_B7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.391.391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 trial)","volume":"126","author":"Attal","year":"2015","journal-title":"Blood"},{"issue":"suppl","key":"2019111706011775600_B8","volume":"34","author":"Cavo","year":"2016","journal-title":"J Clin Oncol"},{"key":"2019111706011775600_B9","first-page":"s104","article-title":"Upfront or rescue transplant in young patients with newly diagnosed multiple myeloma: a pooled analysis of 529 patients","volume":"101","author":"Gay","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2019111706011775600_B10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"issue":"2","key":"2019111706011775600_B11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2019111706011775600_B12","first-page":"CD004626","article-title":"First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies","volume":"10","author":"Naumann-Winter","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2019111706011775600_B13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111706011775600_B14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbmt.2014.12.026","article-title":"Management of relapsed multiple myeloma after autologous stem cell transplant","volume":"21","author":"Holstein","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111706011775600_B15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Salvage second hematopoietic cell transplantation in myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111706011775600_B16","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111706011775600_B17","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"2019111706011775600_B18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2015.325","article-title":"Allogeneic stem cell transplantation for multiple myeloma: is there a future?","volume":"51","author":"Dhakal","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"2019111706011775600_B19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9","key":"2019111706011775600_B20","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111706011775600_B21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111706011775600_B22","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"issue":"9758","key":"2019111706011775600_B23","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"23","key":"2019111706011775600_B24","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"issue":"suppl","key":"2019111706011775600_B25","volume":"33","author":"Straka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111706011775600_B26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111706011775600_B27","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","author":"Myeloma Trialists\u2019 Collaborative Group","year":"2001","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111706011775600_B28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.hoc.2014.06.006","article-title":"Maintenance therapy for multiple myeloma","volume":"28","author":"McCarthy","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"21","key":"2019111706011775600_B29","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"2019111706011775600_B30","volume":"34","author":"Attal","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111706011775600_B31","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2019111706011775600_B32","volume":"33","author":"Holstein","year":"2015","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111706011775600_B33","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111706011775600_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.406.406","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial","volume":"122","author":"Attal","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111706011775600_B35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111706011775600_B36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111706011775600_B37","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111706011775600_B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.27.27","article-title":"Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the HOVON-65\/GMMG-HD4 Trial","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"2019111706011775600_B39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/asheducation-2016.1.485","article-title":"Myeloma: management of the newly diagnosed high-risk patient","volume":"2016","author":"Dispenzieri","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2019111706011775600_B40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.bbmt.2015.10.010","article-title":"Evolution of hematopoietic cell transplantation for immunoglobulin light chain amyloidosis","volume":"22","author":"Sher","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111706011775600_B41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111706011775600_B42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111706011775600_B43","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111706011775600_B44","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/bmt.2013.98","article-title":"Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115","volume":"48","author":"Sanchorawala","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2019111706011775600_B45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.732.732","article-title":"Oral doxycycline improves outcomes of stage III AL amyloidosis\u2013a matched case control study","volume":"126","author":"Wechalekar","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111706011775600_B46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111706011775600_B47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"issue":"19","key":"2019111706011775600_B48","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111706011775600_B49","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.2011.049858","article-title":"Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study","volume":"96","author":"Sanchorawala","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"2019111706011775600_B50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.82.82","article-title":"Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): phase 2 study results","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111706011775600_B51","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111706011775600_B52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.507.507","article-title":"Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1\/2 study (GEN503)","volume":"126","author":"Plesner","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111706011775600_B53","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.505.505","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): Keynote-023","volume":"126","author":"San Miguel","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111706011775600_B54","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111706011775600_B55","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111706011775600_B56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/504\/68448\/hem088352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/504\/68448\/hem088352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T18:15:46Z","timestamp":1601230546000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/504\/21076\/Role-of-stem-cell-transplant-and-maintenance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.504","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}